Referenser

1. Colombel JF, D'Haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. *J Crohns Colitis*. 2020;14(2):254-66.
2. Colombel JF, Narula N, Peyrin-Biroulet L. Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. *Gastroenterology*. 2017;152(2):351-61 e5.
3. Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A. Pharmacokinetics interactions of monoclonal antibodies. *Pharmacological research*. 2016;111:592-9.
4. Oikonomopoulos A, van Deen WK, Hommes DW. Anti-TNF antibodies in inflammatory bowel disease: do we finally know how it works? *Current drug targets*. 2013;14(12):1421-32.
5. Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, *et al*. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. *Gastroenterology*. 2015;149(2):350-5.e2.
6. Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Therapeutic advances in gastroenterology. 2018;11:1756283x17750355.
7. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, *et al*. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. *Clin Gastroenterol Hepatol*. 2004;2(7):542-53.
8. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, *et al*. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. *Gastroenterology*. 2004;126(2):402-13.
9. Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. *Gastroenterology*. 2017;153(3):835-57.e6.
10. Ward MG, Thwaites PA, Beswick L, Hogg J, Rosella G, Van Langenberg D, et al. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. *Aliment Pharmacol Ther*. 2017;45(8):1135-45.
11. Juncadella A, Papamichael K, Vaughn BP, Cheifetz AS. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. *Dig Dis Sci*. 2018;63(11):3067-73.
12. Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. *Aliment Pharmacol Ther*. 2018;47(4):478-84.
13. Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease. *Inflamm Bowel Dis*. 2018;24(10):2266-71.
14. Vermeire S, Dreesen E, Papamichael K, Dubinsky MC. How, When, and for Whom Should We Perform Therapeutic Drug Monitoring? *Clin Gastroenterol Hepatol*. 2020;18(6):1291-9.
15. Ungar B, Glidai Y, Yavzori M, Picard O, Fudim E, Lahad A, *et al*. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases. J Pediatr Gastroenterol Nutr. 2018;67(4):507-12.
16. Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, *et al*. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. *Lancet Gastroenterol Hepatol*. 2019;4(5):341-53.
17. Dreesen E, Baert F, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, *et al*. Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. *Clin Gastroenterol Hepatol*. 2020;18(3):637-46 e11.
18. Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, *et al*. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol*. 2019;17(9):1655-68.e3.
19. Lee SD, Shivashankar R, Quirk D, Zhang H, Telliez JB, Andrews J, *et al*. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. *J Clin Gastroenterol*. 2020.
20. Ungar B, Levy I, Yavne Y, Yavzori M, Picard O, Fudim E, *et al*. Optimizing Anti-TNF-alpha Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol*. 2016;14(4):550-7 e2.
21. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, *et al*. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. *Gastroenterology*. 2005;128(7):1805-11.
22. Gustavsson A, Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, *et al*. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. *Aliment Pharmacol Ther*. 2010;32(8):984-9.
23. Choy MC, Seah D, Faleck DM, Shah SC, Chao CY, An YK, *et al*. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. *Inflamm Bowel Dis*. 2019;25(7):1169-86.
24. Justiniano CF, Aquina CT, Becerra AZ, Xu Z, Boodry CI, Swanger AA, *et al*. Postoperative Mortality After Nonelective Surgery for Inflammatory Bowel Disease Patients in the Era of Biologics. *Ann Surg*. 2019;269(4):686-91.
25. Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. *Gastroenterology*. 2018;155(2):337-46 e10.
26. Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, *et al*. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. *JAMA*. 2017;318(17):1679-86.
27. Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, *et al*. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. *BioDrugs*. 2017;31(4):299-316.
28. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, *et al*. Infliximab, azathioprine, or combination therapy for Crohn's disease. *The New England journal of medicine*. 2010;362(15):1383-95.
29. Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, *et al*. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. *Gastroenterology*. 2014;146(2):392-400.e3.
30. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. *Gut*. 2007;56(9):1226-31.
31. Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, *et al*. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. *Gut*. 2014;63(8):1258-64.
32. Roblin X, Boschetti G, Williet N, Nancey S, Marotte H, Berger A, *et al*. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. *Aliment Pharmacol Ther*. 2017;46(2):142-9.

33. Christophorou D, Funakoshi N, Duny Y, Valats JC, Bismuth M, Pineton De Chambrun G, *et al*. Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis. *Aliment Pharmacol Ther*. 2015;41(7):603-12.
34. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, *et al*. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. *Gastroenterology*. 2008;134(7):1861-8.
35. Roblin X, Williet N, Boschetti G, Phelip JM, Del Tedesco E, Berger AE, *et al*. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. *Gut*. 2020;69(7):1206-12.
36. Hedin C, Halfvarson J. Should we use vedolizumab as mono or combo therapy in ulcerative colitis? *Best Pract Res Clin Gastroenterol*. 2018;32-33:27-34.
37. Allegretti JR, Barnes EL, Stevens B, Storm M, Ananthakrishnan A, Yajnik V, *et al*. Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. *Dig Dis Sci*. 2017;62(6):1590-6.
38. Brassard P, Bitton A, Suissa A, Sinyavskaya L, Patenaude V, Suissa S. Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. *Am J Gastroenterol*. 2014;109(11):1795-802; quiz 803.
39. Subramanian V, Saxena S, Kang JY, Pollok RC. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. *Am J Gastroenterol*. 2008;103(9):2373-81.
40. Toruner M, Loftus EV, Jr., Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, *et al*. Risk factors for opportunistic infections in patients with inflammatory bowel disease. *Gastroenterology*. 2008;134(4):929-36.
41. Dumitrescu G, Amiot A, Seksik P, Baudry C, Stefanescu C, Gagniere C, *et al*. The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab. *Aliment Pharmacol Ther*. 2015;42(10):1192-9.
42. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, *et al*. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet*. 2002;359(9317):1541-9.
43. Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt C, Mantzaris GJ, *et al*. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. *Inflamm Bowel Dis*. 2012;18(11):2026-33.
44. Nagata Y, Esaki M, Umeno J, Fuyuno Y, Ikegami K, Maehata Y, *et al*. Therapeutic strategy for Crohn's disease with a loss of response to infliximab: a single-center retrospective study. *Digestion*. 2015;91(1):50-6.
45. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, *et al*. Infliximab for induction and maintenance therapy for ulcerative colitis. *The New England journal of medicine*. 2005;353(23):2462-76.
46. Taxonera C, Barreiro-de Acosta M, Calvo M, Saro C, Bastida G, Martin-Arranz MD, *et al*. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. *Dig Dis Sci*. 2015;60(10):3075-84.
47. Taxonera C, Olivares D, Mendoza JL, Diaz-Rubio M, Rey E. Need for infliximab dose intensification in Crohn's disease and ulcerative colitis. *World J Gastroenterol*. 2014;20(27):9170-7.
48. Landemaine A, Petitcollin A, Brochard C, Miard C, Dewitte M, Le Balc'h E, *et al*. Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection. *Clin Gastroenterol Hepatol*. 2020.
49. Segaert S, Hermans C. Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents. *Am J Clin Dermatol*. 2017;18(6):771-87.
50. Cohen BL, Fleshner P, Kane SV, Herfarth HH, Palekar N, Farraye FA, *et al*. Anti-Tumor Necrosis Factor Therapy Is Not Associated With Post-Operative Infection: Results From Prospective Cohort Of Ulcerative Colitis And Crohn's Disease Patients Undergoing Surgery To Identify Risk Factors For Post-Operative Infection I (PUCCINI). DDW; San Diego, USA: Gastroenterology 156(6 suppl 1):S-80; 2019.
51. Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, *et al*. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. *J Gastroenterol*. 2018;53(9):1048-64.
52. Shah ED, Farida JP, Siegel CA, Chong K, Melmed GY. Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. *Inflamm Bowel Dis*. 2017;23(4):570-7.
53. Borren NZ, Ananthakrishnan AN. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. 2019;17(9):1736-43 e4.
54. Butter M, Weiler S, Biedermann L, Scharl M, Rogler G, Bischoff-Ferrari HA, *et al*. Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. *Maturitas*. 2018;110:71-8.
55. Lobaton T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. *Aliment Pharmacol Ther*. 2015;42(4):441-51.
56. Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, *et al*. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2013;19(2):309-15.
57. Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D'Inca R, *et al*. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2011;9(1):30-5.
58. Lewis JD, Scott FI, Brensinger CM, Roy JA, Osterman MT, Mamtani R, *et al*. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-alpha-Directed Therapy for Inflammatory Bowel Disease. *Am J Gastroenterol*. 2018;113(3):405-17.
59. Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, *et al*. Comparative safety and effectiveness of tumor necrosis factor alpha antagonists and vedolizumab in elderly IBD patients: a multicentre study. *Aliment Pharmacol Ther*. 2019;49(7):873-9.